Neil Lindsay Berkley Sells 29,251 Shares of Alector (NASDAQ:ALEC) Stock

Posted by Brian Himes on Sep 4th, 2026

Alector, Inc. (NASDAQ:ALEC – Get Free Report) CFO Neil Berkley sold 29,251 shares of the stock in a transaction dated Thursday, September 3rd. The shares were sold at an average price of $2.66, for a total transaction of $77,807.66. Following the completion of the transaction, the chief financial officer directly owned 350,649 shares in the company, valued at $932,726.34. The trade was a 7.70% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Alector Stock Performance

Alector stock traded down $0.05 during trading hours on Friday, hitting $2.46. The company had a trading volume of 496,599 shares, compared to its average volume of 882,288. The firm has a market cap of $274.68 million, a PE ratio of -2.24 and a beta of 0.65. The company has a debt-to-equity ratio of 0.80, a current ratio of 5.26 and a quick ratio of 5.26. Alector, Inc. has a one year low of $1.09 and a one year high of $3.40. The firm has a 50-day moving average of $1.89 and a 200 day moving average of $2.05.

Alector (NASDAQ:ALEC – Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.02. Alector had a negative return on equity of 531.03% and a negative net margin of 850.13%.The company had revenue of $3.32 million during the quarter, compared to analysts’ expectations of $1.71 million. On average, sell-side analysts expect that Alector, Inc. will post -0.87 earnings per share for the current year.

Hedge Funds Weigh In On Alector

Several hedge funds have recently bought and sold shares of the company. BlackRock Inc. acquired a new position in shares of Alector in the 2nd quarter valued at approximately $15,774,000. Vanguard Group Inc. boosted its position in shares of Alector by 0.8% during the 3rd quarter. Vanguard Group Inc. now owns 6,034,659 shares of the company’s stock worth $17,863,000 after acquiring an additional 46,955 shares in the last quarter. Nantahala Capital Management LLC acquired a new stake in shares of Alector during the 2nd quarter worth approximately $8,679,399. Foresite Capital Management IV LLC bought a new position in Alector in the fourth quarter valued at approximately $6,064,000. Finally, Merck & Co. Inc. bought a new position in Alector in the second quarter valued at approximately $7,126,896. 85.83% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the company. Weiss Ratings raised Alector from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 13th. Wall Street Zen raised Alector from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Three analysts have rated the stock with a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $3.62.

View Our Latest Analysis on Alector

About Alector

(Get Free Report)

Alector is a clinical-stage biotechnology company headquartered in South San Francisco, California. Founded in 2013, the company is focused on discovering and developing immuno-neurology therapies that target the innate immune system to treat a range of neurodegenerative disorders. Alector’s approach aims to harness the body’s natural defense mechanisms to clear pathological proteins and restore neuronal function in conditions such as Alzheimer’s disease and frontotemporal dementia.

The company’s pipeline includes multiple product candidates in both preclinical and clinical stages, with lead programs AL001 and AL002 advancing in frontotemporal dementia and Alzheimer’s disease studies.